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Abstract
Background: Knowledge about signaling pathways is typically compiled based on data gathered
using different cell lines. This approach implicitly assumes that the cell line dependence is not
important. However, different cell lines do not always respond to a particular stimulus in the same
way, and lack of coherent data collected from closely related cellular systems can be detrimental
to the efforts to understand the regulation of biological processes. To address this issue, we
created a clone library of human mammary epithelial (HME) cells that expresses different levels of
HER2 and HER3 receptors in combination with endogenous EGFR/HER1. Using our clone library,
we have quantified the receptor activation patterns and systematically tested the validity of the
existing hypotheses about the interaction patterns between HER1-3 receptors.
Results: Our study identified HER2 as the dominant dimerization partner for both EGFR and
HER3. Contrary to earlier suggestions, we find that lateral interactions with HER2 do not lead to
strong transactivation between EGFR and HER3, i.e., EGFR activation and HER3 activation are only
weakly linked in HME cells. We also find that observed weak transactivation is uni-directional
where stimulation of EGFR leads to HER3 activation whereas HER3 stimulation does not activate
the EGFR. Repeating our experiments at lower cell confluency established that cell confluency is
not a major factor in the observed interaction patterns. We have also quantified the dependence
of the kinetics of Erk and Akt activation on different HER receptors. We found that HER3 signaling
makes the strongest contribution to Akt activation and that, stimulation of either EGFR or HER3
leads to significant Erk activation.
Conclusion: Our study shows that clone cell libraries can be a powerful resource in systems
biology research by making it possible to differentiate between various hypotheses in a consistent
cellular background. Using our constructed clone library we profiled the cell signaling patterns to
establish the role of HER2 in the crosstalk between EGFR and HER3 receptors in HME cells. Our
results for HME cells show that the weak linkage between EGFR and HER3 pathways can lead to
distinct downstream cellular signaling patterns in response to the ligands of these two receptors.
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Background
The human epidermal growth factor receptors (HER, also
known as ErbB) belong to the receptor tyrosine kinase
superfamily. They are key regulators of physiological proc-
esses such as cell proliferation, survival, and migration
[1]. The first three members of this receptor family, EGFR/
HER1, HER2 and HER3, play important roles in carcino-
genesis, and they are often co-expressed [2,3]. HER recep-
tors are highly homologous and their activation occurs
through similar biochemical steps, although certain prop-
erties of the receptor members are distinct. For example,
HER2 receptors have no known ligand and HER3 lacks
intrinsic tyrosine kinase activity [4,5], and upon ligand
binding, they all undergo conformation changes that
favor the formation or stabilization of receptor hetero-
and homo-dimers [6,7]. This results in receptor phospho-
rylation, and the resultant formation of complexes with
adaptor proteins to initiate signaling. This cascade of
events leads to downstream signal transduction, and can
trigger diverse biological responses [8-10].
Almost every possible pairwise combination of HER dim-
ers has been reported [11]. Ligand availability [12], the
cellular repertoire of these HER receptors [13], and the
receptor dimerization hierarchy [14,15] are the major
determinants of the dimer formation kinetics. Each HER
receptor appears to have a characteristic repertoire of
adaptor proteins depending on its dimerization partner
[16]. Thus, the types of receptor homo- and hetero-dimers
that are formed, and the signal transduction pathways
that are activated depend upon the specifics of the system
and treatment conditions. This severely complicates the
modeling of the HER signaling pathways and the investi-
gation of the HER-initiated cellular responses [17-20].
Biomedical and biomolecular studies have shown that
inhibition of HER dimerization and HER-mediated sign-
aling can be an extremely effective therapeutic strategy
[21]. In HER2 positive breast cancers, heterodimer inter-
actions between HER2 and its partners are often constitu-
tively activated and their disruption has proven to be an
effective means for inhibiting HER2-mediated aberrant
responses [1,22]. HER3 overexpression has also been
shown to correlate with poor prognosis in epithelial can-
cers [23,24]. Activation of pro-survival responses through
the HER3 pathway can also lead to drug resistance in can-
cer treatment [25,26]. Further, interactions between mem-
bers of the HER family and signaling redundancies can
also contribute to drug resistance when specific inhibitors
are used against a single HER receptor [21,25,27]. Thus,
the use of combination therapeutics that target multiple
members of the HER family of receptors is advocated as an
effective treatment strategy for a variety of tumors
[25,26,28,29].
In terms of downstream elements, HER receptors activate
the MAPK/MEK/Erk and PI3K/PKB/Akt signaling path-
ways [1,8], which are thought to be the general mitogenic
and pro-survival pathways, respectively. Many stimuli,
including growth factors, cytokines, ligands for G protein-
coupled receptors, transforming agents, and carcinogens,
activate the Erk (extracellular signal-regulated kinase)
pathway. Sustained Erk activation can have significant
functional consequences [30,31]. For example, constitu-
tive or prolonged Erk activation through HER receptors
contributes to speedy cell migration [32] and enhances
cell transformation and resistance to apoptosis [33]. The
serine/threonine kinase Akt promotes cellular survival by
blocking apoptosis, which it achieves by binding and reg-
ulating many downstream effectors; e.g., NF-κB, Bcl-2
family proteins, and MDM2 [34]. Akt also induces protein
synthesis and therefore plays a role in tissue growth. Akt
has been implicated in many types of cancers because of
its possible role in angiogenesis and tumor development
[35,36]. In particular HER3 is known to have a unique
ability to efficiently engage the pro-survival PI3K/Akt
pathway [37,38].
As summarized above, many aspects of HER signaling
have been well examined over the years. However, the
body of knowledge has been constructed from in vitro
studies that use different cell lines and treatment condi-
tions. Unfortunately, the characteristics of cellular signal-
ing pathways can be cell line- and condition-dependent,
as evidenced by conflicting reports and incomplete under-
standing about particular aspects of the HER system. For
example, earlier studies have unquestionably established
that HER2 plays a key role in HER signaling. However,
how HER2 functions is still uncertain after numerous
studies. In particular, it is not clear whether HER2 is
merely a preferred dimerization partner of other HER
receptors or whether it mediates lateral information trans-
fer between them [13]. Furthermore, the role of HER2
seems to be different in different cells lines and under dif-
ferent conditions [14]. The existing ideas about the inter-
action mechanisms between the HER receptors [13], and
the role of HER2 in facilitating the interaction between
EGFR and HER3 can be summarized in the form of the
distinct hypotheses illustrated in Figure 1. Briefly, (A)
EGFR and HER3 receptors interact directly, i.e., HER2 is
not required; (B) HER2 is the explicit facilitator of a lateral
interaction; and (C) EGFR and HER3 do not interact with
each other but both of them independently interact with
HER2. In addition to the heterodimerization-mediated
activation of receptors, EGFR can also be activated
through the formation of homodimers. However, HER2,
which does not bind ligand, and HER3, which is kinase
inactive, are only activated through heterodimerization.BMC Cell Biology 2009, 10:78 http://www.biomedcentral.com/1471-2121/10/78
Page 3 of 15
(page number not for citation purposes)
These conflicting observations about the possible role of
HER2 illustrate the context dependence of cellular signal-
ing. Hence, in order to understand the interactions
between the HER molecules under physiological and
pathological conditions, we not only need to study sys-
tems expressing different levels of these receptors, but also
need to do so in a common cellular background to ensure
internal consistency of the generated datasets. This is the
main objective of our study: We have developed a clone
library of human mammary epithelial (HME) cell lines
that express endogenous levels of EGFR and varying levels
of HER2 and HER3 to experimentally examine the various
hypothesized roles of HER2 in coupling EGFR and HER3
activation (Figure 1). Results of our systematic investiga-
tion indicate that, although HER2 is the preferred dimeri-
zation partner for both the EGFR and HER3, it only
weakly couples EGFR and HER3 activation in HME cells.
HER2 plays a significant role in the activation of EGFR
and HER3 in response to their respective ligands, but the
presence of HER2 does not lead to strong crosstalk (trans-
activation) between EGFR and HER3 receptors. We also
find that the observed weak coupling is largely unidirec-
tional, i.e., EGFR ligands can induce HER3 activation in
the presence of HER2 but the stimulation of the HER3
pathway by its ligand does not induce EGFR activation
regardless of the presence of HER2. The receptor activa-
tion patterns reported here provide us with information
on the HER interaction hierarchy in HME cells.
The second objective of our study is to investigate how the
changes in the activation levels of HER1-3 receptors alter
the phosphorylation patterns of downstream effectors Erk
and Akt upon ligand stimulation. In parallel experiments
using the developed clone cell library, EGFR and HER3
were stimulated using their respective ligands EGF and
heregulin (HRG), and Erk and Akt phosphorylation levels
were measured. Our results indicate that HER3 activation
is the strongest inducer of Akt activation in HME cells. We
also observe that, even though it is at a lower level com-
pared to stimulation through the EGFR, Erk activation
occurs at significant levels upon HER3 stimulation. Even
though the observed Akt phosphorylation pattern is simi-
lar to earlier measurements using the MCF-7 human
breast cancer cell line [19], Erk activation patterns in HME
cells are different than in MCF-7 cells [19]. This yet again
shows that a comprehensive investigation of the HER sig-
naling system in a consistent cellular background is war-
ranted.
We note that, unlike many model cell lines with limited
physiological responses to growth factors, HME cells are
an excellent model system for studying the properties of
the HER system because, like many epithelium derived
cell types, HME cells require EGFR activation for proper
proliferation and migration responses [39]. The 184A1
strain of HME cells that was used to develop our clone
library retains the EGFR-dependent regulatory machinery
of the primary cell type from which it was derived [40].
Thus, the data obtained in our study provide relevant
information for developing directed and effective medical
treatments for aberrant responses in epithelial cells.
Methods
Epidermal growth factor (EGF, human recombinant) and
heregulin-β1 (HRG, human recombinant) were pur-
chased from Peprotech (Rocky Hill, NJ). All ELISA assay
kits were purchased from R&D Systems Inc. (Minneapolis,
MN). Humanized monoclonal antibodies 7C2, 2C4 (Per-
tuzumab) and 4D5 (Herceptin, Trastuzumab) were gener-
ous gifts from Genentech, Inc. (South San Francisco, CA).
All the other reagents were from Sigma (St. Louis, MO)
unless otherwise indicated.
Generation of HME Cell Lines
The human mammary epithelial (HME) cell line 184A1L5
was initially provided by Martha Stampfer (Lawrence Ber-
keley Laboratory, Berkeley, CA) and maintained at 37°C
in 5% CO2/air in DFCI-1 medium supplemented with
Schematic diagrams for hypothesized HER receptor inter- action patterns Figure 1
Schematic diagrams for hypothesized HER recep-
tor interaction patterns. These diagrams illustrate the 
EGFR-HER3 interaction patterns that have been reported 
in the literature. (A) EGFR and HER3 receptors interact 
directly, i.e., HER2 is not required; (B) HER2 is the explicit 
facilitator of a lateral interaction; and (C) EGFR and HER3 
do not interact with each other but both of them inde-
pendently interact with HER2. EGFR can also activate itself 
by forming homodimers.
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12.5 ng/ml EGF as described in [41]. This parental cell line
expresses high levels of EGFR and relatively low copy
numbers of HER2 and HER3 and is labeled the HER2-/3-
cell line in our study.
This parental cell line was used to create the HER2 overex-
pressing cell line by retroviral transduction, as described
elsewhere [42]. Briefly, the retroviral MFG vector contain-
ing HER2 was constructed and transfected into the ψ CRIP
packaging cell line [43-45]. The transfected clones with
highest level of HER2 expression were expanded to pro-
duce viral supernatant. This supernatant was then used to
infect the HME cells. Individual clones of retrovirus trans-
duced HME cells were isolated using cloning rings. The
degree of HER2 overexpression was determined by
immunofluorescence, flow cytometry, and equilibrium-
binding studies using labeled Fab fragments. Growth
medium for the HER2 expressing cells was the same as
that of the parental HME cells except for addition of the
antibiotic G418 (250 μg/ml; Invitrogen, Carlsbad, CA) to
ensure selection.
HER3 expressing cells were derived in a similar retrovirus-
based strategy. Retroviral pBM-IRESpuro vector contain-
ing HER3 and the puromycin resistance gene was trans-
fected into the Phoenix packaging cells [46]. Viral
supernatant was collected from transiently transfected
Phoenix cells. The supernatant was then used to infect the
parental HME cells and the HER2 expressing cells (dis-
cussed in the previous paragraph) to create the HER3
expressing and HER2-HER3 coexpressing cell lines,
respectively (Table 1). The cell lines expressing HER3 were
then grown in the DFCI-1 medium with the addition of 2
μg/ml puromycin (Sigma, St. Louis, MO).
The stability of clone cell lines over growth passages was
consistently monitored, and they were stable for at least
20 passages. Still, in our study, only the cells at low pas-
sages were utilized to generate experimental data, and
cells were maintained under G418 and puromycin selec-
tion as appropriate to ensure transduction efficiency. We
note that the parental cell line refers to the original
184A1L5 cells, which were not mock transfected by an
empty vector. We also note that we use the term "cell
library" to refer to our clone library of sub-lines of this
parental HME cell type.
The abundances of HER receptors on all the generated
clones were characterized using flow cytometry, with
Alexa-488 conjugated mAb 7C2 against HER2 and PE
conjugated anti-HER3 antibody (R&D Systems Inc., Min-
neapolis, MN) against HER3, respectively. Expression lev-
els of HER receptors were further confirmed by ELISA
assays.
Cell Activation
When cells grew to near confluency, regular culture
medium was replaced with DFCI-1 medium lacking all
supplements but 0.1% bovine serum albumin. Cells were
then quiescenced for 12-18 hours before stimulation.
Cells were activated through HER receptors by adding
either 12 ng/ml EGF or 40 ng/ml HRG, or both, into the
culture medium. Activated cells were incubated at 37°C
for fixed amounts of time between 0 to 1 hours. Samples
were then collected by cooling cells down to 4°C on ice
and lysing cells using lysis buffer. In the experiments with
antibody blocking, 10 μg/ml antibody (2C4 or 4D5) was
preincubated with cells for four hours before ligand addi-
tion. At least two independent measurements were per-
formed, with two biological replicates in each experiment,
for every treatment condition. Additional experiments
where the cells were grown to ~50% confluency were pur-
sued to investigate the dependence of signaling properties
on cell confluency. Culture plates with 50% confluency
were obtained by seeding the plates with an initial cell
density that was half of those of fully confluent plates.
Cell Lysis
To lyse the cells and prepare samples for receptor mass
and activated/phosphorylated receptor quantification, we
Table 1: Receptor expression levels in HME cell lines
Clone Order of gene transfer Drug selection EGFR (103/cell) HER2 (103/cell) HER3 (103/cell)
HER2-/3- Parental none 200a ± 8 30b 2c, d
HER2+/3- HER2 into HER2-/3- G418 151b ± 5 600a ± 19 2c, d
HER2-/3+ HER3 into HER2-/3- Puromycin 200b ± 7 30b 28 ± 1c
HER2+/3+ HER3 into HER2+/3- G418 and Puromycin 84b ± 7 625b ± 34 28 ± 3c
a An EGFR expression level of 200 K for the HER2-/3- cell line and a HER2 expression level of 600 K for HER2+/3- cell line were reported 
previously [42].
b These EGFR and HER2 expression levels were calculated by normalizing the receptor masses measured in ELISA experiments with the respective 
EGFR and HER2 expression levels shown in item (a) above.
c These HER3 expression levels were calculated by normalizing the receptor masses measured in ELISA experiments with the EGFR receptor 
expression level shown in item (a) above. Detected expression values were validated by re-computing them based on relative readings with respect 
to HER2 expression.
d This is also roughly the detection limit in our ELISA experiments.BMC Cell Biology 2009, 10:78 http://www.biomedcentral.com/1471-2121/10/78
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solubilized cells with ice cold lysis buffer for 20 min (1%
NP-40, 20 mM pH 8.0 Tris buffer, 137 mM NaCl, 10%
glycerol, 2 mM EDTA, supplemented with 1 mM heat acti-
vated sodium orthovanadate and 1% protease inhibitor
cocktail III (Calbiochem, La Jolla, CA)). Cell lysates were
collected with a scraper. Lysates were centrifuged at
13,000 rpm for 10 min at 4°C, and the supernatants were
transferred into fresh microtubes. Obtained cell lysates
were either analyzed immediately or stored at a -80°C
freezer until needed.
The steps to prepare cell lysates for detecting Erk and Akt
and their activation levels were similar as above, except
lysis buffer was replaced with 1 mM EDTA, 0.5% Triton X-
100, 5 mM NaF, 6 M urea, 1 mM activated sodium
orthovanadate, 1% protease inhibitor cocktail III, 100 μM
PMSF and 2.5 mM sodium pyrophosphate, in PBS, pH
7.2-7.4.
Quantification of receptor mass, receptor 
phosphorylation, and Erk/Akt activation
The receptor masses and phosphorylation levels of the
EGFR/HER2/HER3 receptors, and Erk/Akt phosphoryla-
tion levels were quantified in ELISA experiments. R&D
DuoSet IC ELISA kits were used in these measurements.
Before each ELISA assay, protein concentration of cell
lysate was measured using the Bicinchoninic Acid protein
quantitation kit (Sigma, St. Louis, MO). The manufac-
ture's protocol was followed in all ELISA measurements
except for the assays to detect receptor (EGFR/HER2/
HER3) masses (total receptor levels). For the latter, to be
able to monitor the reaction dynamically during our
measurements, the R&D ELISA protocol was modified.
Rather than using streptavidin-HRP to bind a biotinylated
detection antibody, we used streptavidin conjugated with
alkaline phosphatase (Jackson ImmunoResearch, West
Grove, PA) and incubated the assay plate for one hour at
37°C. Afterwards, freshly made 1 mg/ml p-nitrophenyl
phosphate substrate in diethanolamine buffer (10 mM
diethanolamine, 0.5 mM MgCl2, pH9.5) was added to
start the reaction. The absorbance from the ELISA reagents
was detected immediately using a Molecular Devices
microplate reader's kinetic setup at 405 nm for 15 min
(Sunnyvale, CA).
Results
Expression of EGFR/HER2/HER3 in HME Cells
HER receptor expression was examined in all cell lines
using FACS (data not shown). Our previous study indi-
cated an EGFR expression level of 200,000 and a HER2
expression of 20,000 for the parental (HER2-/3-) cell line,
and a HER2 expression level of 600,000 for the HER2
overexpressing clone HER2+/3- [42]. Total receptor
masses were quantified using ELISA assays in all of our
cell lines, and the results were used to estimate the relative
receptor expression levels. Table 1 lists the abundances of
EGFR/HER2/HER3 in our previously reported (HER2-/3-,
HER2+/3-) and newly obtained (a HER3 expresser: HER2-
/3+, and a HER2/3 co-expresser: HER2+/3+) cell lines and
confirms that we have successfully constructed a series of
related HME clones expressing endogenous EGFR and co-
expressing either HER2, HER3, or both. This clone cell
library allows for the systematic examination of the HER
interaction patterns and the impact of different HER
dimer types on downstream signaling and cellular
responses in HME cells. We note that, although we label
HER2-/3- and HER2-/3+ cell lines as HER2 negative these
cells express low levels of HER2. Our labeling is for nota-
tional convenience, and in our case HER2- corresponds to
the endogenous HER2 level and means HER2 was not
transduced.
Receptor activation patterns in HME cell library
We stimulated our cell lines with EGFR ligand (12 ng/ml
= 2 nM EGF), with HER3 ligand (40 ng/ml = 5 nM HRG),
and with both ligands simultaneously. This enabled us to
examine the receptor activation patterns in four cell types
stimulated with three different ligand combinations. We
chose to use different EGF and HRG concentrations
because the response to 2 nM HRG is not as robust as the
response to EGF administration at the same dose. Based
on the measured binding affinities of these two ligands to
their respective receptors [47], the receptor binding ability
of 5 nM HRG is comparable to that of 2 nM EGF, thus
offering a more sensible comparison of EGFR and HER3
pathway activation.
EGFR activation
As shown in Figure 2A, stimulating cells with EGF induced
EGFR phosphorylation within minutes of ligand addition
in all cell lines. Stimulation of the HER3- cell lines with
HRG did not lead to statistically significant EGFR activa-
tion. Our data further indicates that:
i) When stimulated with EGF, the presence of HER2 and/
or HER3 does not have a major impact on the amplitude
of EGFR activation.
ii) The presence of HER2, but not HER3, prolongs EGFR
phosphorylation. The difference in phospho-EGFR decay
rates between HER2-/3- and HER2+/3- cell lines is notice-
able in Figure 2A (p-value = 0.023 when the decay rates
are compared). This is consistent with previous reports
showing that heterodimer formation with HER2 slows the
internalization and degradation of the EGFR thereby pro-
longing EGFR signaling [48]. The p-value is 0.48 when the
decay rates are compared between HER2-/3- and HER2-/
3+ cell lines, which indicate that HER3 by itself does not
significantly affect EGFR phosphorylation. The effect of
HER2 on the EGFR phosphorylation decay is evident evenBMC Cell Biology 2009, 10:78 http://www.biomedcentral.com/1471-2121/10/78
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in cells expressing HER3, although this effect is statisti-
cally less significant (p-value = 0.092 when HER2-/3+ and
HER2+/3+ cells are compared). This indicates that HER2
has a diminished interaction with the EGFR when HER3
is present in the system, most likely due to the competi-
tion because HER2 is also the preferred dimerization part-
ner of HER3.
iii) Activation of HER3 by its ligand HRG does not lead to
sizable EGFR transactivation. Results for HER2-/3+ and
HER2+/3+ cells in Figure 2A show that the stimulation of
the HER3 pathway does not directly activate EGFR regard-
less of the presence of HER2. This observed lack of trans-
activation supports the notion that while HER2 is the
main dimerization partner for the EGFR and HER3 recep-
tors, contrary to earlier suggestions [13], HER2 is not an
HER receptor phosphorylation patterns Figure 2
HER receptor phosphorylation patterns. Phosphorylation levels of (A) EGFR, (B) HER2, and (C) HER3 are compared 
between parental cells (HER2-/3-), HER2 expressing cells (HER2+/3-), HER3 expressing cells (HER2-/3+), and HER2-HER3 co-
expressing cells (HER2+/3+) during one hour time course after activation with low doses of EGF (12 ng/ml), HRG (40 ng/ml), 
or both (EGF+HRG). Samples were collected before ligand addition (t = 0), and at t = 10, 30, and 60 min after ligand addition. 
Receptor phosphorylation levels at these time points are presented as white, black, gray and cross line bars, respectively. 
Results shown here are the means and standard deviations (SD) of at least four measurements from two biological replicates. 
The data for each receptor have been normalized with respect to the receptor phosphorylation level of the HER2+/3+ cell line 
at t = 10 min when both ligands were added.
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efficient lateral information carrier between HER recep-
tors in HME cells (Figure 1B).
iv) EGFR phosphorylation when both EGF and HRG are
added to the system is comparable to when EGF is added
alone (Figure 2A; p-value for the comparison in HER2-/3+
cells is 0.91 and in HER2+/3+ cells is 0.64). This observa-
tion is consistent with item (iii) above, and it shows that
EGFR does not get transactivated following HER3 activa-
tion.
HER2 activation
HER2 receptors are activated at high levels after EGF stim-
ulation in all HER2 expressing HME cell lines (Figure 2B),
and receptor phosphorylation levels are maintained dur-
ing the time course of one hour. We have observed a sim-
ilar dynamic behavior before [17]. This prolonged
activation is also observed when HER2 is stimulated
through HER3 by addition of HRG. We further note that:
i) Even though the HRG concentration used here is 2.5
times that of EGF and the ligand doses are equivalent
when their receptor binding affinities are accounted for
(see above), HER2 receptors are activated at a much lower
levels through the HRG-stimulated HER3 pathway than
through the EGF-stimulated EGFR pathway. However,
this might be due to the lower expression level of HER3 in
our cell library compared to EGFR (Table 1). When the
HER2 phosphorylation results for the HER2+/3+ cell (Fig-
ure 2B) in response to EGF and HRG are normalized with
respect to the EGFR and HER3 expression levels respec-
tively (EGFR/HER3 ratio = 3, Table 1), we find that the
potencies of EGFR and HER3 for inducing HER2 activa-
tion are roughly the same. This implies that HER2 phos-
phorylation in heterodimers with EGFR and HER3 are
comparable.
ii) When HER2 is abundant, its activation through the
EGFR and HER3 pathways are additive. Comparison of
the phospho-HER2 levels in HER2+/3+ cells between
EGF+HRG co-stimulation and only EGF addition yields a
p-value of 0.001. The p-value for the comparison of HER2
phosphorylation by both ligands EGF+HRG in HER2+/3+
and by EGF activation in HER2+/3- cells is 0.019. As
explained below, this suggests that HER2 is the dominant
dimerization partner for EGFR and HER3. The receptor
activation patterns in the system are determined by the
competitive formation of the various dimer types, which
is a complex function of the number of available recep-
tors, the dimerization affinities and the stimulus condi-
tions [17,49]. While it is difficult to measure the receptor
dimerization patterns, it can be deduced by analyzing the
receptor activation profiles in our cell lines. For instance,
if EGFR and HER3 preferentially formed dimers with each
other (Figure 1A), co-stimulation with EGF and HRG
would result in increased phosphorylation of these two
receptors rather than a significant increase in HER2 activa-
tion. This is clearly not the case in our HME system (Figure
2A-C). In contrast, if HER2 is the dominant dimer partner
for EGFR and HER3 (Figure 1C), when there is abundant
HER2, we would expect to see additive HER2 activation
when EGF and HRG are added simultaneously.
HER3 activation
Figure 2C presents HER3 phosphorylation patterns for all
the cell lines under different stimulus conditions. Its lig-
and HRG leads to prominent, prolonged activation of
HER3. The most obvious trend in the HRG stimulated
phosphorylation of HER3 is its strong dependence on
HER2 expression; when HER2 is not present, HER3 phos-
phorylation is low even when it is directly activated by its
own ligand HRG (HER2-/3+ cell line in Figure 2C). This
indicates that HER2 is the main and dominant interaction
partner for HER3 in HME cells, and this conclusion is fur-
ther confirmed in our antibody blocking studies (dis-
cussed below).
Activation of the system with EGF leads to minimal levels
of HER3 phosphorylation. This latter observation further
supports the notion that lateral information transfer from
EGFR activation to HER3 activation is minimal. Graus-
Porta et al have shown that activation of HER3 by EGF can
occur via a direct interaction between HER2 and HER3 in
T47D and SKBR3 cells [13]. Our results in Figure 2C lend
moderate support to this finding: a higher HER2 expres-
sion level leads to a slightly higher HER3 activation upon
EGF stimulation. However, since HER3 activation is min-
imal in EGF stimulated HME cells even when HER2
expression level is high, the coupling between the EGFR
and HER3 activation is very weak in HME cells. It should
be noted that, compared to HER2+/3+ cells, the HER2
expression in HER2-/3+ is very low but this cell line still
expresses HER2 (Table 1). Albeit at a low level, this small
amount of HER2 can still lead to HER3 phosphorylation
when the system is stimulated with HRG (Figure 2C).
Receptor interactions and transactivation patterns
One of our main aims was to determine which of the
existing ideas about the interaction mechanisms between
the HER receptors (Figure 1) was valid in HME cells. Our
results (Figure 2) show that, with the exception of a low
level HER3 activation upon EGF stimulation, the activa-
tion of EGFR and HER3 with their respective ligands does
not strongly transactivate the other receptor. HER3 is acti-
vated at a low level following EGF addition, and this level
of activation is slightly enhanced in the presence of HER2
(compare the results for the HER2-/3+ and HER2+/3+ cell
lines in Figure 2C). These observations lead us to con-
clude that diagram A in Figure 1 is not valid for HME cells.
The lateral information transfer between EGFR and HER3BMC Cell Biology 2009, 10:78 http://www.biomedcentral.com/1471-2121/10/78
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through HER2 suggested by Figure 1B does occur at a low
level in our system but it is not a major contributor to
receptor activation. As both EGFR and HER3 are robustly
activated by their own ligands, and a strong phosphoryla-
tion of HER2 is observed under all stimulus combina-
tions, diagram 1C is the dominant interaction mechanism
between HER receptors in HME cells. Figure 3 summarizes
the observed interaction patterns in HME cells. We note
that transactivation suggested by diagram 1B occurs in a
uni-directional fashion in our system: The presence of
HER2 leads to an increase in HER3 phosphorylation
when cells are activated with EGF. In contrast, EGFR phos-
phorylation in response to HRG is almost non-existent
irrespective of the HER2 expression level (compare HER2-
/3+ and HER2+/3+ cell lines in Figures 2A and 2C). Kim
et al. observed that EGF stimulates HER3 phosphorylation
in COS7 cells [50]. Tzahar et al. have observed that EGFR
coimmunoprecipitates with NDF-activated HER3 in vari-
ous human tumor cell lines, but the EGFR-HER3 complex
was undetectable when cells were stimulated with EGF
[14]. In these studies, activation with EGF led to very low
levels of HER3 phosphorylation [14]. The differences in
EGFR-HER3 transactivation between these previous stud-
ies and ours further highlight the cell line dependence of
HER interactions, and emphasize the need for a system-
atic investigation of HER expression and its consequences
in a common cellular background.
To test whether the lack of observed direct interaction
between EGFR and HER3 was due to the strength of the
stimuli, we have repeated the experiments using saturat-
ing dosages of EGF (100 ng/ml) and HRG (80 ng/ml).
These additional experiments with the HER2-/3+ cells
produced phosphorylation patterns that were similar to
the lower ligand doses (Figure 4), thus supporting our
conclusions.
Data reported in Figure 2 were collected using cultured
cells that were grown to full confluency (see Methods sec-
tion). To test whether cell confluency has an effect on the
observed interaction patterns, we repeated some of the
experiments using cells grown to 50% confluency. Even
though receptor phosphorylation levels are slightly lower
in cells grown to half confluency, we find that the transac-
tivation patterns and overall phosphorylation of the EGFR
and HER3 receptors are very similar across the clones at
full and half confluencies (Figure 5). Thus, cell density
does not have a noticeable impact on the HER receptor
interaction patterns in HME cells.
We note that our current experiments cannot explain the
detailed mechanism of the interactions in diagram 1B,
i.e., whether HER2 performs its intermediary role by
forming multimeric complexes, or by undergoing two dis-
tinct dimerization steps -- first with the EGFR, then with
HER3. The former might be applicable to receptor co-
localization in lipid rafts [51,52]. The latter, where a
receptor dissociates from a dimer and then forms a sec-
ondary dimer with a different receptor type, has also been
suggested as a possible mechanism for lateral information
HER receptor interaction patterns in HME cells Figure 3
HER receptor interaction patterns in HME cells. The 
receptor interaction patterns in HME cells derived based on 
our reported results. Thicknesses of the arrows reflect the 
relative strengths of the interactions.
HER2 
HER2 
EGFR  HER3 
HER2 
EGFR and HER3 phosphorylation in response to high ligand  doses Figure 4
EGFR and HER3 phosphorylation in response to high 
ligand doses. Phosphorylation levels of (A) EGFR and (B) 
HER3 were measured in the HER3 expressing cell HER2-/3+ 
during a two hour time course following activation with 100 
ng/ml EGF, 80 ng/ml HRG, or both ligands simultaneously. 
The white, black, gray, cross line and dotted bars represent 
the receptor phosphorylation levels at t = 0, 10, 30, 60 and 
120 min, respectively. Results shown here are the means and 
SD of two biological replicates. The data in each panel was 
normalized with respect to the phosphorylation level of the 
respective receptor at t = 10 min when both ligands were 
added.
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transfer [13,53]. Whatever the mechanism, we again
emphasize that this type of interaction does not seem to
play a significant role in HME cells.
Effects of HER2 dimerization inhibition on receptor 
activation
Our results shown above and previous studies have clearly
illustrated HER2's central role in modulating HER signal-
ing. To further investigate the interaction patterns in this
receptor family, and to test the validity of the interaction
diagram presented in Figure 3, we used the anti-cancer
antibody 2C4 (pertuzumab) to selectively disrupt the
ability of HER2 to form dimers. The monoclonal antibody
2C4 is considered to be a general inhibitor of HER2
dimerization because of its ability to bind to the HER
dimerization surface [22,54-56]. Since HER2+/3+ cells
express all three receptors, we concentrated on this cell
line, and used the HER2+/3- and HER2-/3+ cell lines as
needed in these validation studies. We predict from our
interaction diagram (Figure 3) that 2C4 would signifi-
cantly lower HER2 phosphorylation under all stimulus
conditions. We also expect that EGFR phosphorylation
will be partially inhibited in the HER2 expressing cell lines
because only the heterodimers with HER2 and not the
EGFR homodimers will be blocked. When HER2 expres-
sion is too low to play a prominent role (HER2-/3+ cells),
EGFR phosphorylation should be left unaffected by 2C4.
In contrast, as HER3 mainly forms heterodimers with
HER2, its phosphorylation should be significantly
decreased in all cases.
Our validation results with the 2C4 antibody are in agree-
ment with these predictions. As predicted, when HER2 is
present, 2C4 only partially decreases EGFR phosphoryla-
tion (20-50%), while EGFR phosphorylation is not
reduced when HER2 is absent (HER2-/3+ cells, Figure
Effect of cell density on HER receptor phosphorylation patterns Figure 5
Effect of cell density on HER receptor phosphorylation patterns. Phosphorylation levels of (A) EGFR and (B) HER3 
are compared between parental cells (HER2-/3-), HER2 expressing cells (HER2+/3-), HER3 expressing cells (HER2-/3+), and 
HER2-HER3 co-expressing cells (HER2+/3+) after activation with low doses of EGF (12 ng/ml), HRG (40 ng/ml), or both 
(EGF+HRG) in cells grown to half or full confluency (described in the Methods section). The legend describes the time points 
and cell confluencies corresponding to each bar in the plot. Results shown here are the means and standard deviations (SD) of 
two measurements from two biological replicates. The data for each receptor have been normalized with respect to the recep-
tor phosphorylation level of the HER2+/3+ cell line at t = 10 min when both ligands were added.
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6A). Robust EGFR phosphorylation in the parental HER2-
/3- cells (Figure 2A) and the moderate decrease in EGFR
phosphorylation in the HER2 expressing cell line upon
2C4 inhibition (Figure 6A) indicate that EGFR homodim-
ers are a major component of EGFR signaling. Although
we observe a significant amount of residual phosphoryla-
tion in all cases, HER2 phosphorylation was largely
(>70%) inhibited by 2C4 in all the cases tested (Figure
6B). We also found that 2C4 decreases HER3 phosphor-
ylation almost down to the detection limit level (>75%
inhibition), regardless of the HER2 expression level (Fig-
ure 6C). This observation indicates that ligand-induced
HER3 activation occurs solely through the formation of
HER2-HER3 dimers.
To further investigate the role of HER2-mediated interac-
tions, we used another HER2 blocking antibody, Hercep-
tin [57] in our HER2+/3+ cells. Like 2C4, 4D5/Herceptin
Inhibition of HER receptor phosphorylation by 2C4 Figure 6
Inhibition of HER receptor phosphorylation by 2C4. HER2 blocking antibody 2C4 was used in these experiments to 
examine the role of HER2 dimerization in the phosphorylation of (A) EGFR, (B) HER2, and (C) HER3. Cells were preincubated 
with antibody 2C4 for 4 hours before addition of 12 ng/ml EGF, 40 ng/ml HRG, or both. The white, black and gray bars repre-
sent the receptor phosphorylation levels at t = 0, 10 and 30 min, respectively. The means and SD of two biological replicates 
are presented.
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also inhibits HER2 dimerization but in a selective fashion;
it disrupts the interaction between EGFR and HER2 but
does not markedly interfere with the HER2-HER3 interac-
tion [58]. This is most likely due to the differential
involvement of HER2 cell surface residues in the forma-
tion of the various dimer types [59,60]. Since in our
derived interaction diagram (Figure 3) HER3 activation
occurs primarily through HER2-HER3 dimerization, we
predict that Herceptin should not significantly affect
HER3 phosphorylation when HER3 is activated with
HRG. We also predict that Herceptin would block HER2
phosphorylation in response to EGF, while minimally
affecting HER2 activation in response to HRG. Further, as
in the 2C4 case, we expect EGFR phosphorylation to be
partially inhibited because only the heterodimers with
HER2 will be blocked, and not the EGFR homodimers.
Our results for EGFR and HER2 phosphorylation in the
presence of Herceptin matched the above predictions
(results not shown). Most importantly, we found that
Herceptin did not have a significant effect on HER3 phos-
phorylation in response to HRG, and to the combined
addition of EGF and HRG in the HER2+/3+ cells (Figure
7). These observations lend further support to our concep-
tual model for HER interactions.
The effect of inhibiting HER2 dimerization on HER3 acti-
vation in response to EGF is also presented in Figure 6C
and Figure 7, and this data can be used to validate the role
of HER2 in EGFR-mediated HER3 transactivation. Based
on our interaction diagram (Figure 3), we predict that
blocking HER2 should diminish HER3 phosphorylation
in response to EGF. Although the HER3 transactivation is
low to begin with, inhibiting HER2 dimerization with
either 2C4 (Figure 6C) or Herceptin (Figure 7) induces a
further decrease in the HER3 activation levels in response
to EGF. This confirms the derived role of HER2 in EGFR-
mediated HER3 transactivation in HME cells.
Downstream signaling in response to HER activation
We have also investigated the activation patterns of Erk
and Akt in HME cells, which are the primary downstream
effectors of the HER family [1,8,37,38]. To characterize
the ability of the various HER receptors to activate Erk and
Akt we assayed the phosphorylation of these signaling
molecules in our clones, which have distinct HER expres-
sion profiles.
HER3 is believed to contribute to pro-survival signaling
through Akt activation [26,34]. Therefore, as expected, Akt
activation (Figure 8A) correlates well with HER3 phos-
phorylation in our HME cell lines. We observed a strong
Akt response when HER3 was activated by HRG. In con-
trast, activation of EGFR with EGF leads to a lower Akt
response (Figure 8A). A similar pattern has been observed
in the MCF-7 cells [19]. However, somewhat surprisingly,
Akt was activated at comparable levels in HER2-/3+ and
HER2+/3+ cell lines in response to HRG (Figure 2C) even
though HER3 phosphorylation levels differed by ~5 fold
in these two cells (Figure 8A). Thus, our results indicate
that even a low HER3 activation level might be enough to
saturate Akt signaling in HME cells. As HER3 signaling
mainly occurs through HER2-HER3 dimers (see above),
this observation emphasizes the strong potency of this
dimer in pro-survival processes. Further, this potency of
the HER2-HER3 dimer could explain why HER3 phos-
Inhibition of HER receptor phosphorylation by Herceptin Figure 7
Inhibition of HER receptor phosphorylation by Herceptin. HER2 blocking antibody Herceptin/4D5 was used in these 
experiments to examine the role of HER2 dimerization in the phosphorylation of HER3. Cells were preincubated with anti-
body Herceptin/4D5 for 4 hours before addition of 12 ng/ml EGF, 40 ng/ml HRG, or both. The white, black and gray bars rep-
resent the receptor phosphorylation levels at t = 0, 10 and 30 min, respectively. The means and SD of two biological replicates 
are presented.
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phorylation is refractory to tyrosine kinase inhibitors that
do not completely silence HER2 [26].
Erk activation was investigated in parallel studies (Figure
8B). Stimulation of the HME cell lines with either EGF or
HRG led to immediate robust Erk activation. Comparison
of the results for the +HRG and +EGF treatments shows
that Erk is more strongly activated by the EGFR pathway
than the HER3 pathway. This is opposite of the trend
observed in the MCF-7 cells [19]. This however could be
due to the unequal EGFR and HER3 expressions and/or
due to the mismatch in the activating ligand concentra-
tions between the studies, which further supports our con-
tention that cellular signaling studies have to be pursued
in a context dependent manner. Studies have also shown
that the Erk pathway can be regulated by PI3K/Akt signal-
ing using different mechanisms. Depending upon the cell
type, on the identity of the agonist and the ligand concen-
tration, the Akt upstream signaling protein PI3K may par-
tially contribute to MEK-dependent Erk activation [61].
Akt itself can also inhibit the Erk pathway through its
effect on Raf activation [62,63]. Comparison of the +EGF
and +EGF+HRG stimulation conditions for the HER3
expressing cells HER2-/3+ and HER2+/3+ shows that Erk
activation does not decrease even though Akt activation is
enhanced ~3 fold (Figure 8). Thus, substantial crosstalk
between Erk and Akt pathways is not apparent in our
HME cells.
Discussion and conclusion
This study reports our results for the receptor activation
profiles in a library of HME cells which express HER2 and
HER3 receptors at different levels and EGFR/HER1 at an
endogenous level. The ability to monitor receptor activa-
tion patterns in closely related cell lines has significant
advantages. Most importantly, this type of systematic
study avoids the ambiguity associated with the interpreta-
tion of results collected in different cell lines. As different
cell lines may not have the same basic cellular machinery
(i.e., their underlying biochemical networks may not be
the same), the dynamics of biomolecular processes can
show strong cell line dependence. This is evidenced by the
contradictory results that often appear in the literature.
Further, even large scale cellular phenotypic responses can
be different in different cell types. The clone cell library
developed in our group provided the means to systemati-
Akt and Erk activation dynamics Figure 8
Akt and Erk activation dynamics. Akt (A) and Erk1 (B) activation patterns in parental cells (HER2-/3-), HER2 expressing 
cells (HER2+/3-), HER3 expressing cells (HER2-/3+), and HER2-HER3 co-expressing cells (HER2+/3+) during one hour time 
course following activation with low dosages of EGF (12 ng/ml), HRG (40 ng/ml), or both (EGF+HRG). Samples were collected 
at t = 0, 10, 30 and 60 min after ligand addition and receptor phosphorylation levels at these time points are presented as 
white, black, gray and cross line bars, respectively. Results are presented as the mean and SD of at least four measurements 
from two biological replicates. The data for each signaling protein was normalized with respect to the phosphorylation level in 
the HER2+/3+ cell line at t = 10 min when both ligands were added.
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cally and quantitatively study the effects of the HER recep-
tor expression profile on signaling patterns in mammary
epithelial cells. The library that we have constructed start-
ing with the 184A1 strain of HME cells is physiologically
relevant for understanding epithelial cell function because
it retains the EGFR-dependent regulatory machinery
needed for proper proliferation and migration. Our
results reveal that our HME cell library recapitulates sev-
eral known features of the HER system, lending further
evidence to its physiological relevance.
We used measurements of the receptor activation patterns
in our cell line library to elucidate the HER interaction
hierarchy, which is difficult to directly quantify. Although
it is possible to use techniques such as fluorescence reso-
nance energy transfer (FRET) or co-immunoprecipitation
(Co-IP) to obtain the relative levels of various dimers,
each of these techniques has drawbacks that complicate
their interpretation particularly when quantification is
desired. FRET requires the use of fluorescent probes or
antibodies that could alter the native conformational
properties of the receptors. With Co-IP, the pull down effi-
ciencies could be different for the different HER dimer
complexes, and transient dimer interactions that result in
receptor activation could be missed. Since receptor inter-
actions are required for the activation of the HER mole-
cules, receptor activation patterns represent a convenient
readout to establish the interaction hierarchy. However, as
evidenced in our discussion of Figures 1 and 3, establish-
ing this link requires careful reasoning because the recep-
tor activation pattern is a complex function of the number
of available receptors, the dimerization affinities and
stimulus conditions.
In this study we have tested various existing hypotheses
about the interactions between HER receptor types in
HME cells. We found that, although HER2 is a preferred
dimerization partner for both EGFR and HER3, it couples
the EGFR and HER3 paths only weakly. These results
invalidate the hypothesis that HER2 acts as a lateral infor-
mation carrier between EGFR and HER3 receptor, a fea-
ture that has been observed in some other cell lines. Our
analysis reveals that the dominant role of HER2 in HME
cells is to amplify EGFR and HER3 signals separately.
Based on our observations, we have constructed a concep-
tual model for HER interactions in HME cells and then
validated our model using the HER2 dimerization block-
ing antibodies 2C4 and Herceptin.
Our observations and the constructed conceptual model
for HER receptor mediated signaling in HME cells can be
useful in several ways. Conceptual models provide the
starting network topology for detailed mechanistic mod-
els. Almost all of the existing mechanistic models for the
HER family of receptors include EGFR-HER3 dimerization
and transactivation (for some recent examples, see
[19,20,49]). Depending on the parameter values, the
EGFR-HER3 heterodimer may even play a major role in
cellular signaling in these models. However, our experi-
mental results have shown that EGFR and HER3 may only
weakly affect each other. Thus, a more correct model
would exclude the EGFR-HER3 dimerization possibility,
at least for our HME cells. Our study clearly allows us to
reach relevant conclusions about the network structures
necessary for mathematical model building efforts.
Another key bottleneck in model building is the lack of
consistent, good quality quantitative data for parameter
estimation. We have recently shown that extracting kinetic
parameters out of the experimental data is not straightfor-
ward, and a model-based analysis of such datasets can be
a powerful tool for establishing the mechanistic details of
the underlying biochemical network for reasonable sized
systems [17]. Chen et al. have recently pursued a similar
but much more ambitious study [20]. Unfortunately these
model building efforts still mix-and-merge kinetic infor-
mation from multiple studies performed for different cell
types under different treatment conditions. Our clone cell
library provides us with the ability to generate consistent
experimental datasets for mathematical modeling,
thereby enabling the quantitative system wide investiga-
tion of the critical HER receptor system.
In addition to the interactions between HER members, we
have also investigated two signaling pathways that are
directly activated by HER receptors, the Akt and Erk sign-
aling pathways, to study the relationship between HER
receptor activation and downstream cellular signaling. We
found that, even though the HER3 pathway's contribution
was comparatively weaker, Erk activation can occur in
response to both EGF and HRG stimulation. Our results
established HER3 as the main contributor to pro-survival
Akt signaling in HME cells. We observed that HER3 acti-
vation with HRG is a strong activator of Akt and that even
low levels of HER3 mediated signaling might be saturat-
ing Akt in HME cells. This could be an indicator for the
limited capacity of the Akt pathway, and have other impli-
cations. Even though EGF induces low levels of Akt activa-
tion, we found that the combined addition of EGF and
HRG results in a slight decrease in Akt activation com-
pared to the addition of HRG alone (Figure 7A). Since
EGFR and HER3 can activate PI3K/Akt through different
recruitment paths [64], when they compete for the limited
PI3K/Akt signaling capacity, the amount of Akt phospho-
rylation reflects the balance between the relative contribu-
tions of the EGFR (weak Akt activator) and HER3 (strong
activator) pathways. Which receptor ends up controlling
Akt activation in a particular cell would depend upon its
receptor expression profile and stimulation condition.
Given that there is only a weak crosstalk between EGFR
and HER3 at the receptor activation level, selectivelyBMC Cell Biology 2009, 10:78 http://www.biomedcentral.com/1471-2121/10/78
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inhibiting EGFR or HER3 depending upon which route
dominates Akt activation could prove to be an effective
therapeutic strategy. As we have shown with examples
here, results reported in this study can be used to develop
and validate new hypothesis about the dynamics of the
HER family of receptors and the downstream pathways
that they activate.
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